- Home
- ODFL vs ALNY Comparison
ODFL vs ALNY Comparison
Compare ODFL & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODFL
- ALNY
- Stock Information
- Founded
- ODFL 1934
- ALNY 2002
- Country
- ODFL United States
- ALNY United States
- Employees
- ODFL N/A
- ALNY N/A
- Industry
- ODFL Trucking Freight/Courier Services
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- ODFL Industrials
- ALNY Health Care
- Exchange
- ODFL Nasdaq
- ALNY Nasdaq
- Market Cap
- ODFL 34.3B
- ALNY 42.9B
- IPO Year
- ODFL 1991
- ALNY 2004
- Fundamental
- Price
- ODFL $164.32
- ALNY $324.79
- Analyst Decision
- ODFL Buy
- ALNY Strong Buy
- Analyst Count
- ODFL 22
- ALNY 25
- Target Price
- ODFL $176.26
- ALNY $347.75
- AVG Volume (30 Days)
- ODFL 1.5M
- ALNY 870.5K
- Earning Date
- ODFL 07-30-2025
- ALNY 07-31-2025
- Dividend Yield
- ODFL 0.68%
- ALNY N/A
- EPS Growth
- ODFL N/A
- ALNY N/A
- EPS
- ODFL 5.33
- ALNY N/A
- Revenue
- ODFL $5,729,595,000.00
- ALNY $2,348,099,000.00
- Revenue This Year
- ODFL N/A
- ALNY $32.73
- Revenue Next Year
- ODFL $7.72
- ALNY $31.50
- P/E Ratio
- ODFL $30.82
- ALNY N/A
- Revenue Growth
- ODFL N/A
- ALNY 17.21
- 52 Week Low
- ODFL $144.90
- ALNY $205.87
- 52 Week High
- ODFL $233.26
- ALNY $333.70
- Technical
- Relative Strength Index (RSI)
- ODFL 49.52
- ALNY 56.23
- Support Level
- ODFL $163.78
- ALNY $320.18
- Resistance Level
- ODFL $174.79
- ALNY $332.19
- Average True Range (ATR)
- ODFL 4.55
- ALNY 7.66
- MACD
- ODFL -0.03
- ALNY -0.44
- Stochastic Oscillator
- ODFL 32.84
- ALNY 67.29
About ODFL Old Dominion Freight Line Inc.
Old Dominion Freight Line is the second-largest less-than-truckload carrier in the United States (following FedEx Freight), with more than 250 service centers and 11,000-plus tractors. It is one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns are head and shoulders above its peers. Strategic initiatives revolve around boosting network density through market share gains and maintaining industry-leading service (including ultralow cargo claims) via steadfast infrastructure investment.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.